Additional data file 15A. DNAme signature in primary Carboplatin-treated

(3) Denoted “TCGA”: Primary ovarian cancer samples (n=342, serous ovarian cancers, median 58 years at diagnosis; 316 received Carboplatin-based chemotherapy), analyzed

Clinicopathological characteristics of ovarian cancer patients (“INNSBRUCK”) for which HOTAIR expression and DNAme has been done (n=134)... * for the entire follow

Patients are stratified into patients who did receive Cisplatin-based chemotherapy (n=26) or received Carboplatin (Carboplatin-Monotherapy or combination

* the log-rank P value (Kaplan Meier statistics; comparing 5 year survival between Carboplatin and Cisplatin treated patients)

(A) Patients with Carboplatin treatment (B) patients without Carboplatin treatment

Hazard ratio (with 95% confidence intervals), likelihood ratio test P-value, and number of data values, for various predictive factors in the Groningen set for a follow up period of

Cox-regression Hazard ratio (with 95% confidence intervals), likelihood ratio test P- value, and number of data values, for various predictive factors in the EUROPE set for full

Cox regression Hazard ratio (with 95% confidence intervals), likelihood ratio test P-value, and number of data values, for various predictive factors in the MAYO